DISCUSSION A new triple GIP, GLP-1 and glucagon receptor agonist called retatrutide has been studied in a high-risk group of CKD patients with diabetes and/or obesity (2, 6, 8)
The name reflects both the skin improvements users report and the acronym-adjacent grouping of Growth (GHK-Cu), Localized healing (BPC-157), and Overall repair (TB-500 and Wolverine)
When to talk to your provider Contact your provider if you experience no appetite suppression after 4 weeks of consistent use, if side effects worsen rather than improve over time, if you develop mouth sores or persistent oral irritation, or if your results plateau significantly after previously good progress
Your personal experience will vary
Additional support may come from collagen peptides and trace minerals.
Who is a good candidate for glp-1